MA47447A - 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer - Google Patents

2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer

Info

Publication number
MA47447A
MA47447A MA047447A MA47447A MA47447A MA 47447 A MA47447 A MA 47447A MA 047447 A MA047447 A MA 047447A MA 47447 A MA47447 A MA 47447A MA 47447 A MA47447 A MA 47447A
Authority
MA
Morocco
Prior art keywords
compounds
dihydropyridazine
heteroaryl
oxo
carboxamides
Prior art date
Application number
MA047447A
Other languages
English (en)
Other versions
MA47447B1 (fr
Inventor
Benjamin Bader
Rafael Carretero
Ilona Gutcher
Horst Irlbacher
Christina Kober
Michael Platten
Ulrike Röhn
Lars Röse
Norbert Schmees
Detlef Stöckigt
Ludwig Zorn
Original Assignee
Bayer Ag
Bayer Pharma AG
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG, Deutsches Krebsforsch filed Critical Bayer Ag
Publication of MA47447A publication Critical patent/MA47447A/fr
Publication of MA47447B1 publication Critical patent/MA47447B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des composés 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide de formule générale (i), dans laquelle x, r1, r2, r3, r4 et r5 sont tels que définis dans la description. L'invention concerne également des procédés de préparation desdits composés, des composés intermédiaires utiles pour préparer lesdits composés, des compositions et des combinaisons pharmaceutiques comprenant lesdits composés, et l'utilisation desdits composés pour fabriquer des compositions pharmaceutiques pour le traitement ou la prophylaxie de maladies, en particulier le cancer ou les maladies avec dérèglement des réponses immunitaires ou d'autres troubles associés aux signaux ahr aberrants, en monothérapie ou en association avec d'autres principes actifs.
MA47447A 2017-02-09 2018-02-02 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer MA47447B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17155406 2017-02-09
EP17202882 2017-11-21
PCT/EP2018/052627 WO2018146010A1 (fr) 2017-02-09 2018-02-02 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA47447A true MA47447A (fr) 2019-12-18
MA47447B1 MA47447B1 (fr) 2021-02-26

Family

ID=61188789

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47447A MA47447B1 (fr) 2017-02-09 2018-02-02 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer

Country Status (39)

Country Link
US (3) US12522594B2 (fr)
EP (1) EP3580211B1 (fr)
JP (1) JP7128826B2 (fr)
KR (1) KR102627266B1 (fr)
CN (3) CN116531380B (fr)
AU (1) AU2018217860B2 (fr)
BR (1) BR112019016497A2 (fr)
CA (1) CA3052718A1 (fr)
CL (1) CL2019002255A1 (fr)
CO (1) CO2019008684A2 (fr)
CR (1) CR20190364A (fr)
CU (1) CU24564B1 (fr)
CY (1) CY1124484T1 (fr)
DK (1) DK3580211T3 (fr)
DO (1) DOP2019000206A (fr)
EC (1) ECSP19057713A (fr)
ES (1) ES2847162T3 (fr)
GE (2) GEAP202115183A (fr)
HR (1) HRP20210143T1 (fr)
HU (1) HUE053191T2 (fr)
IL (1) IL268469B (fr)
JO (1) JOP20190193B1 (fr)
LT (1) LT3580211T (fr)
MA (1) MA47447B1 (fr)
MX (1) MX2019009571A (fr)
MY (1) MY198510A (fr)
NI (1) NI201900085A (fr)
PE (1) PE20191496A1 (fr)
PH (1) PH12019501846A1 (fr)
PL (1) PL3580211T3 (fr)
RS (1) RS61401B1 (fr)
SA (1) SA519402422B1 (fr)
SG (1) SG11201907232XA (fr)
SI (1) SI3580211T1 (fr)
TW (1) TWI770113B (fr)
UA (1) UA124507C2 (fr)
UY (1) UY37606A (fr)
WO (1) WO2018146010A1 (fr)
ZA (1) ZA201905902B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201810366WA (en) * 2016-05-25 2018-12-28 Bayer Pharma AG 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
US12522594B2 (en) 2017-02-09 2026-01-13 Deutsches Krebsforschungszentrum 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
EP3715471A1 (fr) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ensemble de marqueur de signature d'ahr
EP3721894A1 (fr) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Gène 1 induit par l'interleukine-4 (il4i1) en tant que biomarqueur et ses utilisations
CN112724256B (zh) * 2019-10-28 2022-09-16 中国农业大学 一种高稳定性的磺胺类药物抗体hAb 4D11及其应用
EP3835432A1 (fr) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Gène 1 induit par l'interleukine-4 (il4i1) et métabolites respectifs en tant que biomarqueurs pour le cancer
BR112022007837A2 (pt) 2019-12-16 2022-07-05 Bayer Ag Combinação de um inibidor de ahr e um anticorpo inibidor de pd1 e seu uso no tratamento de câncer
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ａｈｒシグナル伝達の調節に有用なピリドピリミジン誘導体
BR112022019387A2 (pt) * 2020-03-27 2022-11-16 Dong A St Co Ltd Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos
WO2021236717A1 (fr) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Dérivés d'imidazole fusionnés utilisés en tant qu'antagonistes d'ahr
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN114369097B (zh) * 2020-10-15 2023-07-14 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114539221B (zh) * 2020-11-27 2026-08-07 苏州泽璟生物制药股份有限公司 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用
CN114685426B (zh) * 2020-12-28 2026-05-26 苏州泽璟生物制药股份有限公司 磺酰胺类抑制剂及其制备方法和应用
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
WO2023043753A1 (fr) * 2021-09-14 2023-03-23 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Modulateurs des récepteurs d'hydrocarbures 2-aryle ou hétéroaryl-3-oxo-4-carbamide-6-cyclique-dihydropyrazine aryle et leur utilisation dans le traitement de maladies et d'affections
US20230190961A1 (en) 2021-10-20 2023-06-22 University Of Rochester Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells
CN119948035A (zh) 2022-10-03 2025-05-06 捷豹治疗有限公司 可用于调节AhR信号传导的化合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU756275B2 (en) * 1998-08-14 2003-01-09 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
JP2000119257A (ja) * 1998-08-14 2000-04-25 Nippon Nohyaku Co Ltd ピリダジノン誘導体
US6358964B1 (en) 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
JP4233868B2 (ja) 2000-09-18 2009-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリダジノンおよびトリアジノン化合物類ならびにそれらの医薬用途
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
DE102004055998A1 (de) 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
CA2586420A1 (fr) 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Amelioration du traitement du cancer et de troubles medies par hif-1 au moyen d'antagonistes des recepteurs de l'adenosine a3
WO2006082952A1 (fr) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited Composé amide
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
AR057986A1 (es) 2005-11-21 2008-01-09 Japan Tobacco Inc Compuesto heterociclico y su uso farmaceutico
EP2023910B1 (fr) 2006-05-03 2013-06-19 Symrise AG ANTAGONISTES DES RéCEPTEURS D'AH
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
DE102006054205A1 (de) 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
US20100210649A1 (en) * 2006-12-21 2010-08-19 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
EP2328586A2 (fr) 2008-05-20 2011-06-08 Cephalon, Inc. Dérivés pyridazinone substitués comme ligands des récepteurs de l'histamine-3 (h3)
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CA2741666C (fr) 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. Antagonistes du recepteur p2x3 pour le traitement de la douleur
US20130338201A1 (en) 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
US10314810B2 (en) 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2015143164A1 (fr) 2014-03-19 2015-09-24 President And Fellows Of Harvard College Agents antimicrobiens et procédés de criblage
SG11201810366WA (en) 2016-05-25 2018-12-28 Bayer Pharma AG 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
US12522594B2 (en) 2017-02-09 2026-01-13 Deutsches Krebsforschungszentrum 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
WO2019090198A1 (fr) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Composés d'isofuranone utiles en tant qu'inhibiteurs de hpk1
EP3713926B1 (fr) 2017-11-21 2023-06-07 Bayer Aktiengesellschaft 4-carboxamides de 2-hetarylpyrimidine comme des antagonistes de l'aryl hydrocarbon receptor
EP3713931B1 (fr) 2017-11-21 2025-03-05 Deutsches Krebsforschungszentrum 3-oxo-6-hétéroaryl-2-phényl-2,3-dihydropyridazine-4-carboxamides
WO2019101642A1 (fr) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 3-oxo-2,3-dihydropyridazine-4-carboxamides substitués par du soufre
US11524944B2 (en) 2017-11-21 2022-12-13 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as AHR inhibitors
CN113015526A (zh) 2018-09-19 2021-06-22 豪夫迈·罗氏有限公司 螺环2,3-二氢-7-氮杂吲哚化合物及其用途
EP3880198A4 (fr) 2018-11-14 2022-08-10 The Broad Institute, Inc. Composés activateurs du récepteur d'aryl hydrocarbone (ahr) en tant qu'agents thérapeutiques contre le cancer
EP4013508A1 (fr) 2019-08-12 2022-06-22 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
WO2021074279A1 (fr) 2019-10-16 2021-04-22 Bayer Aktiengesellschaft Inhibiteurs de map4k1 tricycliques spiro fusionnés
WO2021249913A1 (fr) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft Dérivés de 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azétidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate et des composés apparentés servant d'inhibiteurs de map4k1 (hpk1) pour le traitement du cancer
WO2022167627A1 (fr) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Inhibiteurs de map4k1

Also Published As

Publication number Publication date
UA124507C2 (uk) 2021-09-29
JP2020506946A (ja) 2020-03-05
JOP20190193B1 (ar) 2024-04-18
HUE053191T2 (hu) 2021-06-28
WO2018146010A1 (fr) 2018-08-16
GEAP202115183A (en) 2021-04-12
MX2019009571A (es) 2020-01-20
EP3580211B1 (fr) 2020-12-02
ECSP19057713A (es) 2019-08-30
NI201900085A (es) 2019-11-15
HRP20210143T1 (hr) 2021-03-19
PL3580211T3 (pl) 2021-04-19
SG11201907232XA (en) 2019-09-27
DK3580211T3 (da) 2021-01-25
JP7128826B2 (ja) 2022-08-31
CN110678459B (zh) 2023-04-04
US20260098036A1 (en) 2026-04-09
US20230121195A1 (en) 2023-04-20
RS61401B1 (sr) 2021-02-26
CN116554152A (zh) 2023-08-08
DOP2019000206A (es) 2019-09-30
CN116554152B (zh) 2026-06-26
TWI770113B (zh) 2022-07-11
MY198510A (en) 2023-09-01
JOP20190193A1 (ar) 2019-08-08
IL268469B (en) 2022-04-01
PE20191496A1 (es) 2019-10-21
CU24564B1 (es) 2022-01-13
CO2019008684A2 (es) 2019-08-20
CU20190073A7 (es) 2020-03-04
CL2019002255A1 (es) 2020-01-03
CN116531380B (zh) 2025-11-07
GEP20217281B (en) 2021-08-10
KR102627266B1 (ko) 2024-01-24
TW201840549A (zh) 2018-11-16
AU2018217860B2 (en) 2021-07-08
CA3052718A1 (fr) 2018-08-16
PH12019501846A1 (en) 2020-03-09
US12522594B2 (en) 2026-01-13
CN110678459A (zh) 2020-01-10
UY37606A (es) 2018-09-28
SA519402422B1 (ar) 2021-11-14
CR20190364A (es) 2019-09-27
MA47447B1 (fr) 2021-02-26
LT3580211T (lt) 2021-02-25
ZA201905902B (en) 2021-05-26
ES2847162T3 (es) 2021-08-02
KR20190115460A (ko) 2019-10-11
EP3580211A1 (fr) 2019-12-18
AU2018217860A1 (en) 2019-08-22
US11795164B2 (en) 2023-10-24
CN116531380A (zh) 2023-08-04
US20240294505A1 (en) 2024-09-05
BR112019016497A2 (pt) 2022-05-10
IL268469A (en) 2019-09-26
CY1124484T1 (el) 2022-07-22
SI3580211T1 (sl) 2021-06-30

Similar Documents

Publication Publication Date Title
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA59379B1 (fr) Aminothiazoles substitués en tant qu'inhibiteurs de dgkzeta pour l'activation immunitaire
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA33768B1 (fr) Triazolopyridines
MA51673B1 (fr) Composés pour le traitement des troubles dépendants de kinases
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA41179A (fr) Composés inhibiteurs de parg
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA34308B1 (fr) Triazolopyridines substituées
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA50391B1 (fr) Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale